Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction on April 28, 2026, regarding its previously announced partnership with TARA Mind. The correction addresses the removal of references to Veterans Exploring Treatment Solutions (VETS) from earlier paragraphs of the original release, while reaffirming the collaboration's alignment with a recent executive order aimed at advancing mental health treatments and increasing clinical research participation among veteran communities.
The partnership with TARA Mind is intended to support Phase 3 recruitment for Helus Pharma's HLP003 program in major depressive disorder. HLP003, a proprietary novel serotonergic agonist (NSA), has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. The company's NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, addressing the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is committed to developing proprietary NSAs that aim to provide durable improvements in mental health. In addition to HLP003, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.
The correction underscores the importance of accurate communication regarding partnerships and clinical trial recruitment, especially when involving vulnerable populations such as veterans. The collaboration with TARA Mind aligns with an executive order focused on expanding access to mental health treatments and increasing participation in clinical research. For more details, the full press release is available at https://ibn.fm/re8HL.
Investors and stakeholders can stay updated on the latest news and developments related to Helus Pharma at the company's newsroom: https://ibn.fm/HELP.
